Abstract:Background: This study was designed to investigate the clinical efficacy and safety of Gamma Knife® combined with transarterial chemoembolization (TACE) and immunotherapy in the treatment of primary liver cancer. Aim: To investigate the clinical efficacy and safety of Gamma Knife® combined with TACE and immune-targeted therapy in the treatment of primary liver cancer. Methods: Clinical data from 51 patients with primary liver cancer admitted to our hospital between May 2018 and October 2022 were retrospectively collected. All patients underwent Gamma Knife® treatment combined with TACE and immunotherapy. The clinical efficacy, changes in liver function, overall survival (OS), and progression-free survival (PFS) of patients with different treatment responses were evaluated, and adverse reactions were recorded. Results: The last follow-up for this study was conducted on October 31, 2023. Clinical evaluation of the 51 patients with primary liver cancer revealed a partial response (PR) in 27 patients, accounting for 52.94% (27/51); stable disease (SD) in 16 patients, accounting for 31.37% (16/51); and progressive disease (PD) in 8 patients, accounting for 15.69% (8/51). The objective response rate was 52.94%, and the disease control rate was 84.31%. Alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and alpha-fetoprotein isoform levels decreased after treatment compared with pretreatment (all P = 0.000). The median OS was 26 months [95% confidence interval (95%CI): 19.946-32.054] in the PR group and 19 months (95%CI: 14.156-23.125) in the SD + PD group, with a statistically significant difference (P = 0.015). The median PFS was 20 months (95%CI: 18.441-34.559) in the PR group and 12 months (95%CI: 8.745-13.425) in the SD + PD group, with a statistically significant difference (P = 0.002). Common adverse reactions during treatment included nausea and vomiting (39.22%), thrombocytopenia (27.45%), and leukopenia (25.49%), with no treatment-related deaths reported. Conclusion: Gamma Knife® combined with TACE and immune-targeted therapy is safe and effective in the treatment of primary liver cancer and has a good effect on improving the clinical benefit rate and liver function of patients.

Efficacy of body gamma knife stereotactic radiotherapy on huge hepatocellular carcinoma

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Gamma Knife Surgery for Brain Metastasis from Hepatocellular Carcinoma.

Clinical efficacy and adverse reactions of body gamma knife in treatment of primary liver cancer

Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional planning system combined with transhepatic arterial chemoembolization for treating single large hepatocellular carcinoma: a primary study of survival

The Efficacy of Stereotactic Body Radiotherapy for Patients with Hepatocellular Carcinoma

Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma.

[Prognostic Factors Influencing Survival in Patients with Large Hepatocellular Carcinoma Receiving Combined Transcatheter Arterial Chemoembolization and Radiotherapy].

Clinical efficacy of Gamma Knife® combined with transarterial chemoembolization and immunotherapy in the treatment of primary liver cancer

Transarterial Chemoembolization for Huge Hepatocellular Carcinoma with Diameter over Ten Centimeters: a Large Cohort Study

Evaluation of TACE combined with gamma-knife radiotherapy for primary hepatocellular carcinoma

Evaluation and Adverse reaction of γ-Knife or 3D Intensity-modulated Radiation Therapy Combined with TACE for Patients with Liver Carcinoma

Is hepatectomy for huge hepatocellular carcinoma (≥ 10 cm in diameter) safe and effective? A single-center experience.

Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer

Clinical Effects And Prognostic Factors Of Gyro Knife Radiotherapy In Patients With Hepatocellular Carcinoma

Effect of Perioperative Interventional Therapy on the Gamma Knife in the Treatment of Hepatocellular Cirrhosis and Its Prognosis

Stereotactic Body Radiation Therapy for Small Primary or Recurrent Hepatocellular Carcinoma in 132 Chinese Patients

Clinical Analysis of Stereotactic Body Radiation Therapy Using Extracranial Gamma Knife for Patients with Mainly Bulky Inoperable Early Stage Non-Small Cell Lung Carcinoma

Transcathcter arterial chemoembolization combined with Argon-Helium cryoablation for the treatment of hepatocellular carcinoma of giant lump type: a clinical study

Multiple-electrode radiofrequency ablation of small hepatocellular carcinomas

Abstract No. 39: Transcatheter Arterial Chemoembolization (TACE) Combined Percutaneous Thermal Ablation in Large Hepatocellular Carcinoma: Clinical Observation of the Efficacy and Predictors of Prognostic Factors